FALL RIVER, Wis., Jan. 26, 2021 /PRNewswire/ -- EK, an industry-leading contract manufacturing company located in the heart of Wisconsin, launched a fresh-faced branding campaign and new website to match their incredible growth over the last several years. EK has been quietly growing, incorporating new capabilities, expanding their team, and making a huge impact on the Fall River community through economic growth and youth apprenticeship programs. "It's all about respect," says Gary Errthum, Founder and CEO of EK. "It's about working together and showing respect no matter what your job or title is," Errthum explains when describing EK's key to success. There's no doubt it's working as EK has grown to encompass over 200,000 sq. ft. across two state-of-the-art facilities housing two major divisions: their core business, Complete Manufacturing, and their newest Power Products line. With a team of over 200 people working across three shifts, EK outmatches its competition in comprehensive machining, fabrication, welding, assembly, powder coating, and power system protection products like large-scale generator enclosures. EK's sales and development team set out to re-launch the company's brand to match their success in mid-2020. "Incorporating our history and emphasis on quality was really important to the project." Says
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vaccine program against SARS-CoV-2, which has advanced into Phase 2/3 evaluation. The newly released manuscript describes key safety and immunogenicity data from the U.S. Phase 1 trial for the BNT162b2 vaccine candidate, which at 30µg recorded 7 days after the second dose elicited SARS-CoV-2-neutralizing geometric mean titers (GMTs) in younger adults (18-55 years of age) that were 3.8 times the GMT of a panel of 38 sera of SARS-CoV2 convalescent patients, and in older adults (65-85 years of age) the vaccine candidate elicited a neutralizing GMT 1.6 times the GMT of the same panel, demonstrating strong immunogenicity in younger and older adults. Further, across all populations, BNT162b2 administration was well tolerated with mild to moderate fever in fewer than 20% of the participants. As previously announced, these data informed the companies’ decision to advance a 2-dose regimen of the 30µg dose level of BNT162b2, which encodes an optimized SARS-CoV-2 full-length spike glycoprotein (S), into a Phase 2/3 evaluation. The manuscript is now available on an online preprint server at https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v1 and is concurrently
02:22 AM Sysco Neutral J.P. Morgan 02:19 AM Morgan Stanley Outperform Credit Suisse 02:17 AM QEP Resources Hold Stifel, Nicolaus & Co., Inc. 02:17 AM LHC Group Outperform Credit Suisse 02:15 AM Interpace Biosciences Buy H.C. Wainwright & Co. 02:14 AM Planet Fitnes a Neutral J.P. Morgan 02:11 AM Kodiak Sciences Market Perform BMO Capital Markets 02:10 AM PulteGroup Strong Buy Raymond James Financial, Inc. 02:10 AM MDC Strong Buy Raymond James Financial, Inc. 02:09 AM DR Horton Outperform Raymond James Financial, Inc. 02:08 AM Paccar Strong Buy Raymond James Financial, Inc. 02:07 AM Allison Transmission Strong Buy Raymond James Financial, Inc. 02:06 AM Oshkosh Truck Outperform Raymond James Financial, Inc. 02:05 AM Viatris Outperform Raymond James Financial, Inc. 02:05 AM Triumph Bancorp Outperform Raymond James Financial, Inc. 02:04 AM TCF Financial Outperform Raymond James Financial, Inc. 02:03 AM Kansas City Southern Strong Buy Raymond James Financial, Inc. 02:02 AM Huntington Bancshares Outperform Raymond James Financial, Inc. 02:01 AM Flagstar Bancorp Strong Buy Raymond
1/15/2021 Mirati Therapeutics Buy H.C. Wainwright & Co. 1/15/2021 NVIDIA Positive Susquehanna Financial Group, LLLP 1/15/2021 BlackRock Market Perform BMO Capital Markets 1/15/2021 BlackRock Buy Deutsche Bank 1/15/2021 BlackRock Overweight Barclays Capital 1/15/2021 Asbury Automotive Group Neutral J.P. Morgan 1/15/2021 Monster Beverage Buy Deutsche Bank 1/15/2021 Monster Beverage Neutral Citigroup Corp. 1/15/2021 Sanofi Sell Deutsche Bank 1/15/2021 Anaplan Outperform William Blair 1/15/2021 Customers Bancorp Outperform Wedbush Morgan Securities Inc. 1/15/2021 PureTech Health Outperform SVB Leerink 1/15/2021 CNX Resources Overweight J.P. Morgan 1/15/2021 SOC Teleme a Neutral BTIG Research 1/15/2021 UBS Buy Berenberg 1/15/2021 Cimarex Energy Overweight Morgan Stanley 1/15/2021 WW International Overweight Morgan Stanley 1/15/2021 Voya Financial Overweight Morgan Stanley 1/15/2021 Unum Group Equal Weight Morgan Stanley 1/15/2021 Ecolab Buy Gabelli & Co 1/15/2021 Foot Locker Buy Riley Capital Research 1/15/2021 Targa Resources Overweight Morgan Stanley 1/15/2021 Southwestern Energy Equal Weight Morgan Stanley 1/15/2021 SelectQuote Equal Weight Morgan Stanley 1/15/2021 Range Resources
NEW YORK, Jan. 22, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tyson Foods, Inc. (NYSE: TSN) resulting from allegations that Tyson may have issued materially misleading business information to the investing public. On December 15, 2020, the New York City Comptroller ("NYC Comptroller") called on the Securities and Exchange Commission ("SEC") to open an investigation into Tyson for providing shareholders with "materially false or misleading information regarding Tyson's response to the global COVID-19 pandemic and the resulting risk factors." In a public statement, the NYC Comptroller stated, "There is human cost to Tyson's failures – preventable deaths, hospitalizations and sick workers. These failures have material impacts on its business operations that carry serious risks for shareholders." On this news, Tyson's stock price fell $1.78 per share, or 2.5%, to close at $68.25 per share on December 15, 2020. Rosen Law Firm is preparing a securities lawsuit on behalf of Tyson shareholders. If you purchased securities of Tyson please visit the firm's website at https://www.rosenlegal.com/cases-register-2022.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653
Dear Readers,Has the stock market gotten too predictable for you? Indexes have hovered near record highs for months, and it's been the usual suspects driving moves: stimulus updates, economic-growth prospects, regulation and tax concerns, and maybe a dash of company earnings here and there.
STOCKHOLM, Jan. 18, 2021 /PRNewswire/ -- Fellow Shareholders of Enlabs AB, Alta Fox Capital Management, LLC ("Alta Fox") is one of the largest shareholders of Enlabs AB (NLAB.ST) and currently owns 2,332,625 shares, representing 3.34% of total shares outstanding. Alta Fox does not plan to tender any shares at Entain's (LSE: ENT.L) current offer price of 40 SEK per each Enlabs share. This offer materially undervalues the company, represents a negligible premium of 1.1% to the pre-offer trading price, and has unusual circumstances that make us question why Enlabs' Chairman, Niklas Braathen, accepted such an inadequate offer. The fact that Entain will compensate Braathen as a senior executive post-deal and that the CEO of Entain just announced his departure is highly unusual. It leads us to conclude that while this is a good deal for Entain, it is a bad deal for NLAB minority shareholders. Alta Fox has retained legal counsel to protect our interests in this matter and has spoken with other large shareholders, a portion of which have signed in support of this letter and represent over 10% of total shares outstanding. If Entain wants to acquire NLAB, a highly accretive and strategic asset, Entain must compensate NLAB